GSK's failed trials opened a market niche for Trevi Therapeutics.
1 report, 1 independent
Updated Jul 17
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
GSK's failed trials opened a market niche for Trevi Therapeutics.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Trevi Therapeutics, Inc. is seeking regulatory approval from the FDA for Haduvio, an extended-release formulation of nalbuphine.Sub-event
GSK's trial failure creates a market niche for Trevi Therapeutics.1 source
Keep exploring
The entities involved
-
GSK
British multinational pharmaceutical and biotechnology company
Related events
- GSK gained FDA clearance for a lung cancer medicine, while the FDA began reviewing other highly anticipated drugs.
- Drug approvals are pending from the FDA, while GSK seeks to challenge competitor lung cancer treatments, adding near-approval therapies to its portfolio.
- GSK and Novartis are identified as major pharmaceutical companies.